A patent term extension exists to fix a timing problem that is specific to regulated products. A patent runs for a set term from filing, but a drug or medical device cannot be sold until the FDA finishes reviewing it — and that review can consume years of the patent's life before the product ever reaches the market. 35 U.S.C. 156, enacted as part of the Hatch-Waxman framework, lets the patent owner recover some of that lost time. The statute opens by stating that “The term of a patent which claims a product, a method of using a product, or a method of manufacturing a product shall be extended in accordance with this section from the original expiration date of the patent,” provided the section's conditions are met.

The mechanism is restoration, not a full do-over. Section 156 measures the “regulatory review period” — broadly, the testing and approval time during which the product could not be marketed — and adds a calculated portion of that period back onto the patent's term. It does not return every day spent in review; the statute reduces the period for time attributable to the applicant's own lack of due diligence and for portions of the review that occurred before the patent issued. The result is a partial credit designed to approximate the effective patent life the regulatory process took away.

"The term of a patent which claims a product, a method of using a product, or a method of manufacturing a product shall be extended in accordance with this section from the original expiration date of the patent, which shall include any patent term adjustment granted under section 154(b)..."— 35 U.S.C. 156(a), source

How long can the extension be?

Section 156 imposes two hard ceilings, and both matter. The first is a flat cap on the extension itself: the statute provides that “the period of extension determined on the basis of the regulatory review period determined under any such paragraph may not exceed five years.” No matter how long the FDA review ran, the extension stops at five years. The second ceiling looks at the total remaining life of the patent after the extension is applied. The statute requires that if the remaining term plus the extension “exceeds fourteen years, the period of extension shall be reduced so that the total of both such periods does not exceed fourteen years.” In practice, that means the extended patent cannot give the product more than fourteen years of patent protection running from its approval date.

Those two caps interact. A patent that already has substantial term left at approval will hit the fourteen-year limit first; a patent with little term left may be eligible for closer to the full five years, subject to how much of the regulatory review period the formula credits. The Patent and Trademark Office, working with the FDA, determines the regulatory review period and runs the calculation, so the actual extension a given patent receives is the smaller of what the formula produces and what the caps allow.

It also helps to separate patent term extension from two things it is often confused with. The first is patent term adjustment under 35 U.S.C. 154(b), which compensates for delays caused by the Patent Office during examination; Section 156(a) expressly states that the original expiration date from which an extension runs “shall include any patent term adjustment granted under section 154(b),” so the two stack but arise from different delays. The second is regulatory exclusivity granted by the FDA — such as new-chemical-entity or orphan-drug exclusivity — which is a marketing bar administered under the food-and-drug laws rather than a change to a patent's term. A product's effective protection can rest on patent term, a Section 156 extension, and FDA exclusivities at once, and each is calculated under its own rules. Confusing a regulatory exclusivity with a patent extension produces the wrong expiry date.

One patent, one product, one extension

A further limit governs which patent benefits. Section 156 states that “in no event shall more than one patent be extended under subsection (e)(1) for the same regulatory review period for any product.” A product approved after a single regulatory review can anchor an extension on only one patent, even when several patents in a portfolio cover the product, its method of use, or its manufacture. The owner must therefore choose which patent to extend — typically the one whose extended expiry best protects the franchise. To obtain the extension, the statute requires that “the owner of record” of the patent file an application meeting the section's procedural requirements within the statutory window.

For the biotech and pharmaceutical estate, patent term extension is the difference between a patent's nominal expiration date and its commercially effective one. A nominal expiry tells you when the twenty-year term ends; only after accounting for any Section 156 extension — and the five-year and fourteen-year caps that bound it — can you state when a product's principal patent protection actually lapses. Reading the extension into the timeline is what separates a paper expiry date from the date that matters for biosimilar or generic entry.

The interaction between Section 156 and the rest of a franchise's protection is what makes the extension consequential rather than technical. A blockbuster biologic or small-molecule drug whose principal composition patent receives a Section 156 extension can see its commercially effective expiry move years past its nominal twenty-year date, and that shifted date is the one that governs when generic or biosimilar entry becomes possible. Because the statute permits only one extended patent per regulatory review period, the choice of which patent to extend is itself a strategic act with multi-year revenue consequences, and it must be made within the procedural window the statute sets. Analysts mapping an exclusivity cliff therefore cannot stop at the patent's face expiration; they have to locate any Section 156 extension on the record and apply both the five-year and fourteen-year caps before stating when protection ends.

This is a description of what 35 U.S.C. 156 provides; it is not legal advice, and the extension available for any particular patent depends on the PTO and FDA determinations and the full statutory calculation.